Arcutis Biotherapeutics Inc (ARQT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.57B
Last updated: Nov 17, 2026 at 11:04 AM ET
Arcutis Biotherapeutics Inc (ARQT) Stock Forecast
Analysts expect Arcutis Biotherapeutics (ARQT) to earn $0.33 per share in the fiscal year ending Dec 31, 2026, on revenue of $542.15M. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.88, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 5 | 62.5% |
| Hold | 1 | 12.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 230.3% and revenue estimates rise 29.7%.
- Fiscal year ending Dec 31, 2026
- $0.33
- EPS consensus, revenue $542.15M
- Fiscal year ending Dec 31, 2027
- $1.09
- EPS consensus, revenue $703.01M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.33 | $0.24 to $0.64 | 7 | $542.15M | $540.00M to $544.30M | 8 |
| Dec 31, 2027 | $1.09 | $0.52 to $1.84 | 7 | $703.01M | $671.96M to $779.40M | 8 |
Quarterly Estimates
The EPS consensus falls from $0.19 for the quarter ending Dec 31, 2026 to $0.06 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.19 | $0.14 to $0.33 | 10 | $166.22M | $157.68M to $173.36M | 9 |
| Mar 31, 2027 | $0.06 | -$0.09 to $0.14 | 4 | $145.53M | $133.80M to $152.10M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 19.5% from $0.41.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.33 | $0.43 | $0.43 | $0.41 | $0.41 | -20.5% |
| Fiscal year ending Dec 31, 2027 | $1.09 | $1.34 | $1.36 | $1.30 | $1.30 | -16.0% |
| Quarter ending Mar 31, 2027 | $0.06 | $0.08 | $0.12 | $0.12 | $0.12 | -52.2% |
Frequently Asked Questions About ARQT
What is the ARQT stock forecast?
Consensus analyst estimates put Arcutis Biotherapeutics's EPS at $0.33 for the fiscal year ending Dec 31, 2026, on revenue of $542.15M. The consensus rating from 8 analysts is Buy.
How do analysts rate ARQT stock?
Of 8 analysts covering Arcutis Biotherapeutics, 2 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ARQT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.33, with estimates from $0.24 to $0.64 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.09, with estimates from $0.52 to $1.84 from 7 analysts.
What revenue do analysts expect from Arcutis Biotherapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $542.15M, with estimates from $540.00M to $544.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $703.01M, with estimates from $671.96M to $779.40M.
How many analysts cover ARQT?
8 analysts rate Arcutis Biotherapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ARQT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors